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Introduction
Acentralnervoussystemrelapseisaseriouscomplication
ofaggressivelymphomas.Prognosisisgenerallyregarded
as poor and standard therapies of relapsed central
nervous system lymphoma (CNSL) have not yet been es-
tablished [1]. In contrast, therapeutic results have been
much better in primary CNS lymphomas (PCNSL) with a
regimen developed by our group, consisting of combined
systemicandintraventricularchemotherapywithdeferred
radiotherapy and applied within a pilot/phase II study in
65 patients [2]. The overall response rate was 71% for
the whole group, median time to treatment failure (TTF)
was 21 months, and median overall survival 50 months.
Results were significantly better in patients <60 years of
age with a 86% overall response rate and a 75% survival
fraction at five years.
CNSrelapseiscommoninacutelymphaticleukemia(ALL)
andBurkittlymphoma(30–50%),lesscommon(2–10%)
in diffuse large B cell lymphoma (DLBCL). In indolent
lymphomaCNSrelapseis0–4%,inmantlecelllymphoma
4–23% [3], [4].
In DLBCL CNS relapse occurs in median 5–12 months
fromoriginaldiagnosis.Leptomenigeal(33–100%)occur-
rence is more frequent than parenchymal (10–56%). In
half of the cases of CNS relapse there is an additional
systemic relapse. Median survival is only 2–6 months
[3],[4],[5],[6],[7],[8],[9].High-dosechemotherapywith
stem cell transplantation leads to a median event free
survival (EFS) of 0.4 to 1.5 years and an overall survival
(OS) of 0.8 to 2.2 years [10]. A pilot study with MTX/Ifo
has been recently performed [4].
Since data on secondary central nervous system lymph-
oma(SCNSL)islimited,anefficienttherapyhasnotbeen
established yet [1]. Therefore, we have retrospectively
evaluated the clinical characteristics and outcome of
SCNSL patients at our centers.
Patients and methods
Eligibility criteria, initial treatment and
patient characteristics
AllpatientswithSCNSLtreatedatBonnUniversityHospit-
al and Cologne University Hospital from 04/2003–
12/2007 were included into the analysis. 23 patients
could be identified.
60%ofpatientshadaDLBCL,30%afollicularlymphoma,
10% presented with other histologic subtypes.
Patients with SCNSL had received 6–8 cycles of CHOP
(Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Pred-
nisone)orCHOP-likecombinationchemotherapyasinitial
treatment. At cerebral relapse, 4/23 patients received
anacuteleukemiaregimen(GMALL-B-ALLprotocol),3/23
patients received whole brain irradiation to a total of
40 Gy in 2 Gy fractions alone, one was treated with a
chemotherapy according to the BEAM protocol and
autologous bone marrow transplantation and 15/23 pa-
tients received a combined systemic and intraventricular
polychemotherapy according to the Bonn protocol
(Table 1). Systemic high-dose MTX was administered as
a 24 h infusion under vigorous hydration, urine alkaliza-
tion and preconditions as well as dose modifications as
described in [2]. Ifosfamide, cyclophosphamide, ARA-C,
vinca-alkaloids and dexamethasone (cycles 3 to 6) were
administered as described in [2]. In patients developing
a peripheral neuropathy under treatment, application of
vinca-alkaloids was omitted in subsequent cycles. Dexa-
methasone, if given postoperatively, was tapered and
omitted during the first cycle.
18/23 patients (78%) were male with 13 /23 patients
(57%) being older than 60 years. The median age at dia-
gnosis was 60 years (range 41–77).
Evaluation of response and toxicity
Response criteria were used in line with recommenda-
tionsoftheInternationalPrimaryCentralNervousSystem
Lymphoma Collaborative Group (IPCG) consensus (for
primary CNS lymphomas), and therefore all respective
magnetic resonance imaging (MRI) studies were re-eval-
uated for this analysis according to these criteria [11]:
Complete response (CR) was defined as disappearance
of all enhancing lesions on MRI of the brain in patients
beingoffsteroids,unconfirmedcompleteresponse(CRu)
was defined as a minimal residual enhancing lesion in
the region of biopsy/hemorrhage without change or with
involution during follow up, partial response (PR) as re-
duction of enhancing tumor volume by more than 50%,
progressive disease (PD) as increase of tumor volume of
more than 25% or occurrence of new lesions and stable
disease(SD)asanyothersituation[12].Treatmentfailure
was defined as PD or SD, relapse after initial response,
death or discontinuation of chemotherapy due to any
cause. Acute toxicity was graded according to the WHO
system [13].
Statistics
Students T-test was used to analyse for statistical signi-
ficance. A p-value <0.05 was considered significant. For
probability of survival calculations, the Kaplan-Meier
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Sequence of cycles: A1 (d. 1–5), B1 (d. 22–26), C1 (d. 43–49); A2 (d. 64–68), B2 (d. 85–89), C2 (d. 106–112). Cycles A to C
(A1 to C1) are repeated once (A2 to C2).
methodwasusedandwaspresentedgraphicallybySPSS
(SPSS Inc., Chicago, Illinois, U.S.A. Version 11.5.1).
Results
The response rates of the pooled cohort of patients with
SCNSL were as follows: CR in 12 cases, PR in 3 cases,
and PD in 8 cases (overall response: 65%). Interestingly,
response rates were higher with the Bonn protocol as
compared to the ALL protocol (Table 2).
Median overall survival was 7 months (Figure 1). The
predictive value of age on the overall survival time was
analysed. Among the patients who suffered from SCNSL,
median OS averaged 7 months for patients <60 years
(n=10) and 12 months for the group =60 years (n=13),
respectively (Figure 2).
After a median follow-up of 6.5 months (range 1–68),
15/23 (65%) patients with SCNSL relapsed a second
time (n=5) or progressed (n=10). The respective five pa-
tients with recurrence all showed a relapsed within the
CNS. Median time to relapse was 20 months. Eleven
cases were submitted to salvage therapy at time of
second relapse or PD, whereas 4 patients with a PD did
not receive another therapy because of an “early death”
or a decline in general condition. For 4/5 patients, treat-
ment at relapse consisted of radiotherapy and 1/5 pa-
tientsreceivedapolychemotherapyaccordingtotheBonn
protocol for PCNSL. Response to relapse treatment was
in one case CR, in one case PR, and in 3 cases PD
(Table2,Table3).TreatmentatsecondPDwasradiother-
apy alone (n=4), radiotherapy in combination with temo-
zolomide (n=1), and BEAM chemotherapy (n=1). Re-
sponse to treatment was in one case PR and in 5 cases
PD (Table 3). Patients without specific treatment (n=4)
suffered from PD, as expected.
Prognosis of relapsed/progressive SCNSL was dismal.
Median OS was short with only 7 months survival time
after relapse. 15/23 patients (65%) with a relapse or a
PD died within the observation period due to complica-
tions of CNS relapse (Figure 3).
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Figure 1: Overall survival of patients with SCNSL
Figure 2: Overall survival of patients with SCNSL according to age of patients
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Figure 3: Survival function according to the outcome after initial treatment
Discussion
CNS relapse in patients with aggressive lymphoma is
uncommon. The cumulative incidence is only 2.8% and
2.2%, respectively [14], [15]. However, the prognosis of
patients with CNS relapse is dismal.
IncontrasttoclinicaltrialsinPCNSL,therarityofsecond-
ary central nervous system lymphoma is one of the
reasons why prospective trials on this entity are difficult
to perform. Therefore, there is only limited data on treat-
ment strategies for SCNSL. At present there is a clinical
trial running in Germany.
However, since in our centers results with a combined
systemic and intraventricular MTX-based chemotherapy
has resulted in very promising results in PCNSL [2], we
favored this regimen in the majority of patients with
SCNSL that came to our institutions.
Our series includes 23 patients diagnosed and treated
for SCNSL between 2003 and 2007. 15/23 patients
(65%) received the same therapy at cerebral relapse as
patients with PCNSL (data not shown), which consisted
of high-dose methotrexate (MTX) in combination with
vincristine,ifosfamide,prednisoloneandcytarabine(Bonn
protocol). Yet, compared to other studies on SCNSL that
reported median survival times from 1–5 months [14],
[15], [16] and response rates under 50%, our series
confirmstheviewofdifferentauthors,thatearlyintroduc-
tion of HD-methotrexate is important when treating sec-
ondary CNS lymphoma as well as PCNSL and is associ-
ated with longer survival [1], [16].
The age of the patients at the time of diagnosis was pre-
dictive for the survival time among the patients with
PCNSL. Patients younger than 60 years old had a signifi-
cantly longer survival time than patients who were more
than 60 years old (37 months/13 months) (p<0.001). In
contrast to PCNSL, a statistically significant association
between the age of the patients and long-term survival
fortheSCNSL-collectivecouldnotbeverified.Thisismost
likely due to the comparatively small group of only 23
evaluated patients with SCNSL in our series. However,
most reported studies, with a collective of over 100 pa-
tients, recognized age as a predictor for longer survival
times[1],[17].Therefore,treatmentstrategiesforSCNSL
mustbeadjustedtothepatient’sage,inasimilarfashion
to the previously modified treatments for PCNSL.
A median follow-up of 6.5 months (range 1–68) showed
that15patientswithaSCNSL(65%)relapsedafterinitial
response or progressed within the CNS. Treatment at re-
lapse/progression was heterogeneous dependent of the
regimens applied at first relapse and due to the lack of
approved and established treatment strategies for such
clinicalcourses.56%ofthepatientswithsecondcerebral
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the response rate of patients with a refractory disease
was only 14%, respectively. Relapse or PD of the lymph-
oma dims the high overall response rates after initial
treatment for SCNSL in both groups and leads to the re-
spectively poor prognosis. Therefore, new treatment
strategies for PCNSL and SCNSL are needed to prevent
the risk of relapse and refractory disease.
In conclusion, HD-MTX chemotherapy according to the
BonnProtocoliseffectiveinSCNSLpatientsalthoughthe
prognosis of patients with SCNSL seems to be worse as
compared to PCNSL patients. Prognosis of relapsed and
refractoryCNSLpatientsisdismal.Medianoverallsurvival
was only 7.1 months in patients with SCNSL. Therefore,
new treatment strategies are urgently needed.
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